These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 16077922)

  • 1. The effects of interleukin-7 on the lymphangiogenic properties of human endothelial cells.
    Al-Rawi MA; Watkins G; Mansel RE; Jiang WG
    Int J Oncol; 2005 Sep; 27(3):721-30. PubMed ID: 16077922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo.
    Al-Rawi MA; Watkins G; Mansel RE; Jiang WG
    Br J Surg; 2005 Mar; 92(3):305-10. PubMed ID: 15672426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
    Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
    Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo.
    Jiang WG; Davies G; Martin TA; Parr C; Watkins G; Mansel RE; Mason MD
    Int J Mol Med; 2005 Oct; 16(4):723-8. PubMed ID: 16142411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential implication of IL-24 in lymphangiogenesis of human breast cancer.
    Frewer NC; Ye L; Sun PH; Owen S; Ji K; Frewer KA; Hargest R; Jiang WG
    Int J Mol Med; 2013 May; 31(5):1097-104. PubMed ID: 23546515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer.
    Ming J; Zhang Q; Qiu X; Wang E
    Eur J Cancer; 2009 Mar; 45(5):866-73. PubMed ID: 19136250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread.
    Schneider M; Büchler P; Giese N; Giese T; Wilting J; Büchler MW; Friess H
    Int J Oncol; 2006 Apr; 28(4):883-90. PubMed ID: 16525637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of lymphangiogenic markers in human gastroenteric tumor.
    Yuanming L; Feng G; Lei T; Ying W
    Arch Med Res; 2007 Jan; 38(1):106-12. PubMed ID: 17174733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interleukin 7 and its receptor promote cell proliferation and induce lymphangiogenesis in non-small cell lung cancer].
    Ming J; Zhang QF; Jiang YD; Jiang GC; Qiu XS
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):511-8. PubMed ID: 23157741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour expression of lymphangiogenic growth factors but not lymphatic vessel density is implicated in human cervical cancer progression.
    Sotiropoulou N; Bravou V; Kounelis S; Damaskou V; Papaspirou E; Papadaki H
    Pathology; 2010 Dec; 42(7):629-36. PubMed ID: 21080871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells.
    Zhuo W; Luo C; Wang X; Song X; Fu Y; Luo Y
    J Pathol; 2010 Nov; 222(3):249-60. PubMed ID: 20814900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-lymphangiogenesis effects of a specific anti-interleukin 7 receptor antibody in lung cancer model in vivo.
    Jian M; Qingfu Z; Yanduo J; Guocheng J; Xueshan Q
    Mol Carcinog; 2015 Feb; 54(2):148-55. PubMed ID: 24115038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis.
    Sipos B; Kojima M; Tiemann K; Klapper W; Kruse ML; Kalthoff H; Schniewind B; Tepel J; Weich H; Kerjaschki D; Klöppel G
    J Pathol; 2005 Nov; 207(3):301-12. PubMed ID: 16161179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The specific effect of 2-methoxyestradiol on lymphatic vascular endothelial cells.
    Imai S; Yoshida Y; Okamura T; Nagano K; Abe Y; Yoshikawa T; Kamada H; Nakagawa S; Tsunoda S; Tsutsumi Y
    Pharmazie; 2009 Mar; 64(3):214-6. PubMed ID: 19348346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and cellular mechanisms of lymphangiogenesis.
    Al-Rawi MA; Mansel RE; Jiang WG
    Eur J Surg Oncol; 2005 Mar; 31(2):117-21. PubMed ID: 15698725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma.
    Zhang B; Wang J; Gao J; Guo Y; Chen X; Wang B; Gao J; Rao Z; Chen Z
    J Cell Biochem; 2009 May; 107(1):134-43. PubMed ID: 19241443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 7 induces the growth of breast cancer cells through a wortmannin-sensitive pathway.
    Al-Rawi MA; Rmali K; Mansel RE; Jiang WG
    Br J Surg; 2004 Jan; 91(1):61-8. PubMed ID: 14716795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate.
    Hong YK; Harvey N; Noh YH; Schacht V; Hirakawa S; Detmar M; Oliver G
    Dev Dyn; 2002 Nov; 225(3):351-7. PubMed ID: 12412020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.